

What is claimed is

1. A method for treating a hematopoietic disease, wherein the method comprises administering any one of the proteins selected from the group consisting of (a) to (d) shown below, or a
5 polynucleotide encoding the protein:
 - (a) a protein comprising the amino acid sequence of SEQ ID No: 2;
 - (b) a protein comprising an amino acid sequence with one or more amino acid substitutions, deletions, insertions, and/or additions in the amino acid sequence of SEQ ID No: 2, wherein the protein is functionally equivalent to a protein comprising the amino acid sequence of
10 SEQ ID No: 2;
 - (c) a protein encoded by a polynucleotide that hybridizes under stringent conditions with a polynucleotide comprising the nucleotide sequence of SEQ ID No: 1, wherein the protein is functionally equivalent to a protein comprising the amino acid sequence of SEQ ID No: 2; and
 - (d) a protein encoded by a polynucleotide comprising a nucleotide sequence with at
15 least 70% or more homology to the nucleotide sequence of SEQ ID No: 1, wherein the protein is functionally equivalent to a protein comprising the amino acid sequence of SEQ ID No: 2.
2. The method of claim 1, wherein the hematopoietic disease is a disease caused by abnormal
20 erythroblast differentiation.
3. The method of claim 1, which comprises introducing a hematopoietic stem cell with a vector that harbors a polynucleotide in an expressible state.
4. A method for inducing erythroblast differentiation, wherein the method comprises
25 expressing in a hematopoietic stem cell any one of the proteins selected from the group consisting of (a) to (d) shown below.
5. A pharmaceutical formulation for treating a hematopoietic disease, wherein the formulation comprises as an effective ingredient any one of the proteins selected from the group consisting of
30 (a) to (d) shown below, or a polynucleotide encoding the protein:
 - (a) a protein comprising the amino acid sequence of SEQ ID No: 2;
 - (b) a protein comprising an amino acid sequence with one or more amino acid substitutions, deletions, insertions, and/or additions in the amino acid sequence of SEQ ID No: 2, wherein the protein is functionally equivalent to a protein comprising the amino acid sequence of
35 SEQ ID No: 2;
 - (c) a protein encoded by a polynucleotide that hybridizes under stringent conditions

with a polynucleotide comprising the nucleotide sequence of SEQ ID No: 1, wherein the protein is functionally equivalent to a protein comprising the amino acid sequence of SEQ ID No: 2; and

(d) a protein encoded by a polynucleotide comprising a nucleotide sequence with at least 70% or more homology to the nucleotide sequence of SEQ ID No: 1, wherein the protein is functionally equivalent to a protein comprising the amino acid sequence of SEQ ID No: 2.

6. The pharmaceutical formulation of claim 5, which is a hematopoietic stem cell harboring the polynucleotide in an expressible state.

7. A method for treating a hematopoietic disease, wherein the method comprises administering an agent that enhances the activity of a protein comprising the amino acid sequence of SEQ ID No: 2.

8. A therapeutic agent for a hematopoietic disease, which comprises an agent that enhances the activity of a protein comprising the amino acid sequence of SEQ ID No: 2 as an effective ingredient.

SEQUENCE LISTING

<110> Nakajima, Toshihiro
Amano, Tetsuya
Yagishita, Naoko

<120> Essential Role of Synoviolin/HRD1 in Embryonic Hematopoiesis

<130> BHP-PRV0301/US

<140>

<141>

<160> 2

<170> PatentIn Ver. 2.0

<210> 1

<211> 3374

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (403).. (2256)